This is a summary of the European public assessment report (EPAR) for Anagrelide Viatris (previously Anagrelide Mylan). It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Anagrelide Viatris. For practical information about using Anagrelide Viatris, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Anagrelide Viatris is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy. An at-risk patient An at-risk essential thrombocythaemia patient is defined by one or more of the following features: • >60 years of age or • a platelet count >1,000 x 10⁹/l or • a history of thrombo-haemorrhagic events.
Therapeutic Area (MeSH)
N/AATC Code
L01XX35
ATC Item
anagrelide
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| anagrelide hydrochloride | N/A | 阿那格雷 |
EMA Name
Anagrelide Viatris (previously Anagrelide Mylan)
Medicine Name
Anagrelide Viatris (previously Anagrelide Mylan)
Aliases
N/ANo risk management plan link.
